![]() Ambulatory pump infusion (API) chemotherapy is technically feasible and has improved patient tolerance to chemotherapy while demonstrating similar, if not comparable, antitumor effects. ![]() Phase III comparative trials of intermittent bolus therapy with protracted infusion therapy are in progress for 5-Fu in advanced colorectal cancer and for adriamycin in specific tumors. Adverse effects were significantly reduced, particularly with regard to gastrointestinal toxicity, but also in adriamycin-associated cardiac effects and hair loss. For example, the user programs an infusion rate of 10 mL/hour, but the device. Therapeutic effects were observed for three of four drugs studied: 5-Fu 13/31 colorectal cancer adriamycin 7/29 and vinblastine 4/12, including 2/4 melanoma. The infusion pump interprets a single keystroke as multiple keystrokes (a problem called a key bounce). This schedule allowed for increased cumulative drug dose for 5-Fu, decreased tolerated dose for vinblastine, and comparable doses for adriamycin and mitomycin-C relative to that delivered with the standard intermittent bolus schedule. Drug was administered via a tunneled subclavian line by a battery-driven peristaltic pump (Cormed model ML6) on an ambulatory basis. ![]() ONE HUNDRED TWENTY-FOUR PATIENTS with meta-static malignancy were treated with four different single agent infusion programs by constant intravenous infusion for 30 or more days.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |